CROSSJECT's Commitment During the Summer Months
CROSSJECT, the innovative pharmaceutical company, is staying engaged throughout the summer, ensuring that essential operations continue unabated despite the seasonal break.
Ongoing Maintenance and Production Preparedness
At CROSSJECT’s production facilities, vital maintenance operations are being executed diligently. These preparations are crucial for resuming production on a solid footing to facilitate smooth commercial deliveries once operations fully restart.
The company is committed to maintaining operational excellence. Summer breaks often mean a shutdown in many industries, but CROSSJECT has organized its teams to prioritize activities that sustain progress in key projects.
Regulatory Submissions and Development Progress
One of the central focuses of CROSSJECT is the submission of the ZEPIZURE® dossier for Emergency Use Authorization (EUA). The regulatory teams are working tirelessly, collecting relevant documents that bolster their application. Continuous communication between teams is vital during this stage, and it underscores the company’s commitment to advancing its products through the regulatory process.
Additionally, throughout August, the development teams are intensively working on the New Drug Application (NDA) for ZEPIZURE®, which is positioned as a rescue therapy for epilepsy. This involves careful monitoring and analysis of production processes, reviewing comprehensive documentation, and gearing up for an upcoming clinical study poised to take place in the United States.
Leadership Insights on Summer Operations
Patrick Alexandre, Chairman of the Executive Board of CROSSJECT, highlighted the organization’s commitment despite the seasonal lull. He stated, “Although the summer break is a good time to shut down production lines, our teams are organized to ensure the continuity of internal activities and those with our partners that are necessary for the progress of ZEPIZURE® registrations on the US market.” This sentiment reflects a proactive approach to maintaining momentum even when typical operations may slow.
About CROSSJECT and Its Innovative Technologies
CROSSJECT SA is a forward-thinking company specializing in emergency pharmaceuticals, utilizing its award-winning ZENEO® needle-free auto-injector technology. This advanced platform is designed to facilitate the effortless delivery of emergency medications through intramuscular injection, ensuring that patients or untrained caregivers can act quickly in critical situations.
Among its noteworthy projects is ZEPIZURE®, aimed at providing immediate epilepsy relief, which is supported by a substantial contract with BARDA totaling $60 million. The versatility of the ZENEO® platform is also being harnessed for various other emergency treatments, including responses to allergic shocks and adrenal insufficiencies. CROSSJECT is dedicated to broadening its reach and enhancing patient care through innovative solutions.
For any inquiries, investors can reach out to CROSSJECT's Investor Relations at investors@crossject.com.
Frequently Asked Questions
What is CROSSJECT's primary area of focus?
CROSSJECT specializes in developing emergency medications delivered through their needle-free auto-injector technology.
What is the significance of the ZEPIZURE® dossier?
The ZEPIZURE® dossier is crucial for obtaining Emergency Use Authorization, ensuring the product can be used in urgent situations.
How is CROSSJECT maintaining operations during the summer?
The company has organized its teams to ensure continuous engagement in regulatory and developmental activities even while conducting maintenance at production sites.
What is the ZENEO® platform?
The ZENEO® platform is CROSSJECT's proprietary needle-free auto-injector technology designed for the easy delivery of emergency drugs.
How can investors reach CROSSJECT for more information?
Investors can contact CROSSJECT's Investor Relations via email at investors@crossject.com.
